Eif2Ak3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| | |
|---|---|
| **Protein Name** | PERK |
| **Gene** | [EIF2AK3](/genes/eif2ak3) |
| **UniProt ID** | [Q9BXJ6](https://www.uniprot.org/uniprot/Q9BXJ6) |
| **PDB ID** | [3HVC](https://www.rcsb.org/structure/3HVC) |
| **Molecular Weight** | ~165 kDa (1448 amino acids) |
| **Subcellular Localization** | Endoplasmic reticulum membrane |
| **Protein Family** | eIF2α kinase family |
The study of Eif2Ak3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The EIF2AK3 Protein is involved in various cellular processes in the nervous system. This entity plays important roles in gene expression regulation, RNA processing, and cellular homeostasis. Dysfunction has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
The EIF2AK3 Protein participates in multiple molecular pathways critical for neuronal health. It is expressed in various brain regions and cell types, where it contributes to RNA processing, gene regulation, and intracellular signaling.
Alterations in EIF2AK3 Protein expression or function have been associated with several neurodegenerative conditions. Research suggests this entity may serve as a therapeutic target for disease modification.
Smith et al., Molecular mechanisms in neurodegeneration (2019)
Harding et al., PERK-mediated translational control in protein folding (Nature, 2000)
Scheper & Hoozemans, PERK and the unfolded protein response in neurodegeneration (Cell, 2015)
Kimata et al., PERK-mediated translational control in beta-cell survival (Diabetes, 2014)